



Lhasa Japan Symposium 2024, Draft Agenda

 **10th September**
 **9:30-18:00, JST**
 **Tokyo**

9:30-10:00 Registration and Welcome

- Dr Chris Barber, CEO, **Lhasa Limited**

10:00-12:00 Session 1 | Mastering ICH M7 Assessment Using *In Silico* Tools | *In silico* を用いた変異原性不純物評価について

- Dr Angela White, Computational Toxicologist, **GSK**
- Dr Gabriela Silveira, Senior Application Scientist, **Lhasa Limited**
- Dr Andrew Teasdale, Senior Principal Scientist, Impurity Management & External Advocacy, Chair AZ Impurities Advisory Group, **AstraZeneca**
- Dr Michael Burns, Principal Scientist, **Lhasa Limited**

12:00-13:00 Lunch

13:00-17:00 Session 2 | Optimising Nitrosamine Risk Assessment | ニトロソアミンリスク評価について

- Mr Yosuke Mino, Principal Research Scientist, Product Development Laboratories, **Japan Tobacco**
- Dr Kiyohiro Hashimoto, Associate Scientific Fellow, Drug Safety Research and Evaluation Research, **Takeda Pharmaceutical Company**
- Dr Chris Smith, Principal Scientist I, Analytical Operations, Alberta Manufacturing Analytical Operations, **Gilead Alberta**
- Dr Rachel Hemingway, Principal Scientist, **Lhasa Limited**
- Mizuki Ebihara, Application Scientist, **Lhasa Limited**
- Dr David Ponting, Principal Scientist, **Lhasa Limited**
- Dr Gabriela Silveira, Senior Application Scientist, **Lhasa Limited**

17:00-17:30 Session 3 | Regulatory Advice from EMA on Nitrosamine Risk Assessment | ニトロソアミンリスク評価に関するEMAからの規制助言

- Dr Martin Walter, MSc MScTox (ERT), **Austrian Agency for Health and Food Safety & European Medicines Agency**

17:30-18:00 Q&A and Close

- Dr Crina Heghes, CEO, **Consult Lhasa**
- Dr Chris Barber, CEO, **Lhasa Limited**

18:00-19:00 Networking

